Diphtheria - Pipeline Review, H2 20111

Document Sample
Diphtheria - Pipeline Review, H2 20111 Powered By Docstoc
					Diphtheria – Pipeline Review, H2 20111

                           Diphtheria - Pipeline Review, H2 20111
                                                                                          Reference Code: GMDHC1280IDB

                                                                                          Publication Date: August 2011

Diphtheria – Pipeline Review, H2 20111                                                                            GMDHC1280IDB / Pub August 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
Diphtheria – Pipeline Review, H2 20111

Ta b le o f Co n te n ts
Table of Contents                                                                                                  2
List of Tables                                                                                                     5
List of Figures                                                                                                    6
Introduction                                                                                                       7
     Global Markets Direct Report Coverage                                                                         7
Diphtheria Overview                                                                                                8
Therapeutics Development                                                                                           9
     An Overview of Pipeline Products for Diphtheria                                                               9
Diphtheria Therapeutics under Development by Companies                                                            11
Diphtheria Therapeutics under Investigation by Universities/Institutes                                            12
Late Stage Products                                                                                               13
     Comparative Analysis                                                                                         13
Mid Clinical Stage Products                                                                                       14
     Comparative Analysis                                                                                         14
Early Clinical Stage Products                                                                                     15
     Comparative Analysis                                                                                         15
Pre-Clinical Stage Products                                                                                       16
     Comparative Analysis                                                                                         16
Diphtheria Therapeutics - Products under Development by Companies                                                 17
Diphtheria Therapeutics - Products under Investigation by Universities/Institutes                                 19
Companies Involved in Diphtheria Therapeutics Development                                                         20
     Sanofi-Aventis                                                                                               20
     GlaxoSmithKline plc                                                                                          20
     Merck & Co., Inc.                                                                                            21
     Mitsubishi Tanabe Pharma Corporation                                                                         21
     LG Life Sciences, Ltd                                                                                        22
Diphtheria - Therapeutics Assessment                                                                              23
     Assessment by Monotherapy Products                                                                           23
     Assessment by Combination Products                                                                           24
     Assessment by Route of Administration                                                                        25
     Assessment by Molecule Type                                                                                  27
Drug Profiles                                                                                                     29
     V501 + Menactra + Adacel - Drug Profile                                                                      29
          Product Description                                                                                     29
          Mechanism of Action                                                                                     29
          R&D Progress                                                                                            29
     GSK2202083A + Prevenar 13 + Rotarix - Drug Profile                                                           31
          Product Description                                                                                     31
          Mechanism of Action                                                                                     31
          R&D Progress                                                                                            31
     Actacel - Drug Profile                                                                                       32
          Product Description                                                                                     32
          Mechanism of Action                                                                                     32
          R&D Progress                                                                                            32
     DTaP-Hep B-PRP-T Vaccine - Drug Profile                                                                      33
          Product Description                                                                                     33
          Mechanism of Action                                                                                     33

Diphtheria – Pipeline Review, H2 20111                                                    GMDHC1280IDB / Pub August 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                           Page(2)
Diphtheria – Pipeline Review, H2 20111

          R&D Progress                                                                                            33
     GSK2202083A + Synflorix - Drug Profile                                                                       35
          Product Description                                                                                     35
          Mechanism of Action                                                                                     35
          R&D Progress                                                                                            35
     DTaP-IPV-HB-PRP~T + Prevnar - Drug Profile                                                                   36
          Product Description                                                                                     36
          Mechanism of Action                                                                                     36
          R&D Progress                                                                                            36
     Daptacel + IPOL + Menactra - Drug Profile                                                                    38
          Product Description                                                                                     38
          Mechanism of Action                                                                                     38
          R&D Progress                                                                                            38
     Heptavalent Combination Vaccine - Drug Profile                                                               39
          Product Description                                                                                     39
          Mechanism of Action                                                                                     39
          R&D Progress                                                                                            39
     Hexavalent Combination Vaccine - Drug Profile                                                                40
          Product Description                                                                                     40
          Mechanism of Action                                                                                     40
          R&D Progress                                                                                            40
     Tdap - Drug Profile                                                                                          41
          Product Description                                                                                     41
          Mechanism of Action                                                                                     41
          R&D Progress                                                                                            41
     GSK217744 Formulation B + Prevenar 13 - Drug Profile                                                         42
          Product Description                                                                                     42
          Mechanism of Action                                                                                     42
          R&D Progress                                                                                            42
     GSK217744 Formulation A + Prevenar 13 - Drug Profile                                                         44
          Product Description                                                                                     44
          Mechanism of Action                                                                                     44
          R&D Progress                                                                                            44
     Hexaxim - Drug Profile                                                                                       46
          Product Description                                                                                     46
          Mechanism of Action                                                                                     46
          R&D Progress                                                                                            46
     Quadracel - Drug Profile                                                                                     47
          Product Description                                                                                     47
          Mechanism of Action                                                                                     47
          R&D Progress                                                                                            47
     DTaP-HepB - Drug Profile                                                                                     48
          Product Description                                                                                     48
          Mechanism of Action                                                                                     48
          R&D Progress                                                                                            48
     DtwP-HB-Hib Vaccine - Drug Profile                                                                           49
          Product Description                                                                                     49
          Mechanism of Action                                                                                     49

Diphtheria – Pipeline Review, H2 20111                                                    GMDHC1280IDB / Pub August 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                           Page(3)
Diphtheria – Pipeline Review, H2 20111

          R&D Progress                                                                                                                        49
     DtwP-HB-Hib (Recon) Vaccine - Drug Profile                                                                                               50
          Product Description                                                                                                                 50
          Mechanism of Action                                                                                                                 50
          R&D Progress                                                                                                                        50
     DtwP-HB Vaccine - Drug Profile                                                                                                           51
          Product Description                                                                                                                 51
          Mechanism of Action                                                                                                                 51
          R&D Progress                                                                                                                        51
     BK-4SP - Drug Profile                                                                                                                    52
          Product Description                                                                                                                 52
          Mechanism of Action                                                                                                                 52
          R&D Progress                                                                                                                        52
     V419 + Pentacel + Prevnar 13 + RotaTeq - Drug Profile                                                                                    53
          Product Description                                                                                                                 53
          Mechanism of Action                                                                                                                 53
          R&D Progress                                                                                                                        53
     DTP-HepB-Polio-Hib - Drug Profile                                                                                                        55
          Product Description                                                                                                                 55
          Mechanism of Action                                                                                                                 55
          R&D Progress                                                                                                                        55
     V419 + Daptacel + PedvaxHIB + Prevnar 13 + RotaTeq - Drug Profile                                                                        56
          Product Description                                                                                                                 56
          Mechanism of Action                                                                                                                 56
          R&D Progress                                                                                                                        57
Diphtheria Therapeutics – Drug Profile Updates                                                                                                58
Diphtheria Therapeutics - Discontinued Products                                                                                               59
     Diphtheria -
Description: Diphtheria - Pipeline Review, H2 20111 Summary Global Markets Direct’s, 'Diphtheria - Pipeline Review, H2 2011', provides an overview of the Diphtheria therapeutic pipeline. This report provides information on the therapeutic development for Diphtheria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diphtheria. 'Diphtheria - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Diphtheria. - A review of the Diphtheria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diphtheria pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Diphtheria. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries